OncoMatch/Clinical Trials/NCT06557421
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
Is NCT06557421 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Venetoclax and Azacitidine for acute myeloid leukemia.
Treatment: Venetoclax · Azacitidine — The goal of this clinical trial is to test efficacy and safety of a VENETOCLAX-AZACITIDINE (VEN-AZA) de-escalation strategy in Acute Myeloid Leukemia responding patients. The main objectives of the study are: * Evaluation of the efficacy of VEN-AZA de-escalation strategy by measuring the effect of VEN-AZA discontinuation in term of Disease-Free Survival. * Evaluation of the other efficacy parameters and safety of VEN-AZA de-escalation strategy. Patients from the prospective study will be compared to a retrospective cohort of patients who will be selected on the basis of identical eligibility criteria. Participants will: * Stop VEN-DASA treatment * Be closely monitored by regular evaluation of the disease
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: venetoclax and azacitidine (venetoclax, azacitidine) — first-line
VEN-AZA given as first-line treatment; Duration of VEN-AZA therapy of 12 months (+/- 28 days), regardless of duration of VEN-AZA cycles and the doses
Cannot have received: venetoclax and azacitidine (venetoclax, azacitidine)
VEN-AZA given as salvage therapy
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06557421 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages